Benchmark Co. Reiterates a Buy Rating on Natera

By Jason Carr

In a report released today, Raymond Myers from Benchmark Co. reiterated a Buy rating on Natera (NASDAQ: NTRA), with a price target of $20. The company’s shares opened today at $10.

According to, Myers is a 2-star analyst with an average return of 1.8% and a 37.5% success rate. Myers covers the Healthcare sector, focusing on stocks such as Staar Surgical Company, Foundation Medicine, and Chembio Diagnostics.

Natera has an analyst consensus of Moderate Buy.

The company has a one year high of $13.80 and a one year low of $6.52. Currently, Natera has an average volume of 201.5K.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NTRA in relation to earlier this year.

Natera, Inc. operates as a genetic testing company, which develops proprietary bioinformatics-based technology. It provides preconception and prenatal genetic testing services for in-vitro fertilization clinics to identify genetic diseases and chromosomal abnormalities in embryos prior to implantation. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.